The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Second‐generation antipsychotic effect on cognition in patients with schizophrenia—a meta‐analysis of randomized clinical trials
Abstract
Objective: To investigate the effect of second‐generation antipsychotics on cognitive function in patients diagnosed with schizophrenia or schizoaffective disorder. Method: Multiple‐treatments meta‐analysis model. Results: On cognitive composite score, sertindole was superior to clozapine, effect size (ES) 0.87; 95% CI: 0.12–1.63, quetiapine, ES 0.75; 95% CI: 0.00–1.49, and first‐generation antipsychotics (FGA s), ES 0.89; 95% CI: 0.14–1.64. Analyses on each cognitive domain showed clozapine, ES 0.37; 95% CI: 0.00–0.74, olanzapine, ES 0.31; 95%CI: 0.02–0.59, quetiapine, ES 0.34; 95% CI: 0.03–0.64, and FGA s, ES 0.51; 95% CI: 0.18–0.83 performing poorer on verbal working memory than ziprasidone, as well as FGA s performing poorer than risperidone, ES 0.31; 95% CI: 0.04–0.58. On executive function, sertindole performed better than clozapine, ES 0.82; 95% CI: 0.06–1.58, olanzapine, ES 0.81; 95% CI: 0.07–1.55, quetiapine, ES 0.76; 95% CI: 0.02–1.51, ziprasidone, ES 0.90; 95% CI: 0.14–1.67, and FGA s, ES 0.83; 95% CI: 0.08–1.58. On processing speed, FGA s performed poorer than sertindole, ES 0.97; 95% CI: 0.02–1.91, and quetiapine, ES 0.36; 95% CI: 0.01–0.72. On long‐term verbal working memory, clozapine performed poorer than olanzapine, ES 0.41; 95% CI: 0.06–0.76. On verbal fluency, FGA s performed poorer than olanzapine, ES 0.26; 95% CI: 0.01–0.50, and clozapine, ES 0.44; 95% CI: 0.06–0.81. Lastly, FGA s, ES 0.41; 95% CI: 0.04–0.78, and clozapine, ES 0.44; 95% CI: 0.05–0.83, performed poorer on visuospatial skill compared to olanzapine. Conclusion: The meta‐analysis was able to detect some trends in the data analyzed, but did not show any drug having a uniform positive cognitive profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 1×
“In the recent years, multiple-treatment meta-analysis (MTMA), also termed a network meta-analysis, have increasingly been used to investigate the effects of psychotropic drugs (20, 21), as the statistical model allows for investigation of not only all directly compared drug—drug combinations, for example, head-to-head…”
BackgroundSelf-citationCipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Conceptual and technical challenges in network meta-analysis
Cipriani, A., Higgins, J. P. T., Geddes, J. R., & Salanti, G. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00008 · Cited by 1,072
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
Green, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., Fenton, W. S., Frese, F., Goldberg, T. E., Heaton, R. K., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.023 · Cited by 919
Keefe, R. S. E., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033374 · Cited by 693
Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500516x · Cited by 605
Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dubé, S., Mallinckrodt, C., Bymaster, F. P., McKinzie, D. L., & Felder, C. C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.06091591 · Cited by 560
Cullum, C. M. (2013) · Behavioral Neurology & Neuropsychiatry · doi:10.1017/cbo9781139016919.026 · Cited by 544
Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
Purdon, S. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.249 · Cited by 469
Buchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426
Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.799 · Cited by 397
Goldberg, T. E., Goldman, R. S., Burdick, K. E., Malhotra, A. K., Lencz, T., Patel, R. C., Woerner, M. G., Schooler, N. R., Kane, J. M., & Robinson, D. G. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1115 · Cited by 394
Longitudinal studies of cognition in schizophrenia: Meta-analysis
Szöke, A., Trandafir, A., Dupont, M.-E., Méary, A., Schürhoff, F., & Leboyer, M. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.029009 · Cited by 331
Rosenheck, R. (2003) · JAMA · doi:10.1001/jama.290.20.2693 · Cited by 326
Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W. W., Keefe, R. S., Boter, H., Keet, I. P. M., Prelipceanu, D., Rybakowski, J. K., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08060806 · Cited by 320
Mishara, A. L., & Goldberg, T. E. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.027 · Cited by 310
de Gracia Dominguez, M., Viechtbauer, W., Simons, C. J. P., van Os, J., & Krabbendam, L. (2009) · Psychological Bulletin · doi:10.1037/a0014415 · Cited by 308
Association of Anticholinergic Load With Impairment of Complex Attention and Memory in Schizophrenia
Minzenberg, M. J., Poole, J. H., Benton, C., & Vinogradov, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.116 · Cited by 283
Buchanan, R. W., Holstein, C., & Breier, A. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90082-5 · Cited by 281
Clozapine alone versus clozapine and risperidone with refractory schizophrenia
Honer, W. G., Thornton, A. E., Chen, E. Y. H., Chan, R. C. K., Wong, J. O. Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053222 · Cited by 277
Keefe, R. S. E., Sweeney, J. A., Gu, H., Hamer, R. M., Perkins, D. O., McEvoy, J. P., & Lieberman, J. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1061 · Cited by 276
Correll, C. U. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)71701-6 · Cited by 273
Effect of second-generation antipsychotics on cognition: current issues and future challenges
Hill, S. K., Bishop, J. R., Palumbo, D., & Sweeney, J. A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.143 · Cited by 233
Fervaha, G., Foussias, G., Agid, O., & Remington, G. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12289 · Cited by 231
Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia
Mohamed, S., Rosenheck, R., Swartz, M., Stroup, S., Lieberman, J. A., & Keefe, R. S. E. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111713 · Cited by 203
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone
Green, M. F., Marder, S. R., Glynn, S. M., McGurk, S. R., Wirshing, W. C., Wirshing, D. A., Liberman, R. P., & Mintz, J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01370-7 · Cited by 202
Effects of clozapine on cognitive function in schizophrenia.
Lee, M. A., Thompson, P. A., & Meltzer, H. Y. (1994) · PubMed · Cited by 196
Does cognitive function improve with quetiapine in comparison to haloperidol?
Velligan, D. I., Newcomer, J., Pultz, J., Csernansky, J., Hoff, A. L., Mahurin, R., & Miller, A. L. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00268-7 · Cited by 183
Gallhofer, B., Bauer, U., Lis, S., Krieger, S., & Gruppe, H. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)00010-7 · Cited by 177
Purdon, S. E., MALLA, A. K., Labelle, A., & Lit, W. (2001) · PubMed · Cited by 177
Meltzer, H. Y., Bobo, W. V., Roy, A., Jayathilake, K., Aygun, C., Elif, E. A., Yagcioglu, A., & Small, J. G. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0214 · Cited by 176
Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis
Désaméricq, G., Schurhoff, F., Meary, A., Szöke, A., Macquin-Mavier, I., Bachoud-Lévi, A. C., & Maison, P. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1600-y · Cited by 161
Keefe, R. S. E., Young, C. A., Rock, S. L., Purdon, S. E., Gold, J. M., & Breier, A. F. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.038 · Cited by 159
Harvey, P. D., Green, M. F., McGurk, S. R., & Meltzer, H. Y. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1342-5 · Cited by 156
Buchanan, R. W., Keefe, R. S. E., Umbricht, D., Green, M. F., Laughren, T., & Marder, S. R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq038 · Cited by 154
Harvey, P. D., Patterson, T. L., Potter, L. S., Zhong, K., & Brecher, M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1918 · Cited by 152
Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.08.021 · Cited by 146
Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol
Sergi, M. J., Green, M. F., Widmark, C., Reist, C., Erhart, S. M., BRAFF, D. L., Kee, K. S., Marder, S. R., & Mintz, J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06091515 · Cited by 128
The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine
Kern, R. S., Green, M. F., Cornblatt, B. A., Owen, J. R., McQuade, R. D., Carson, W. H., Ali, M. W., & Marcus, R. N. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0428-x · Cited by 127
Rodefer, J. S., Nguyen, T. N., Karlsson, J.-J., & Arnt, J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301654 · Cited by 126
Lee, M., Jayathilake, K., & Meltzer, H. Y. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00145-5 · Cited by 120
Lindenmayer, J., Khan, A., Iskander, A., Abad, M. T., & Parker, B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0303 · Cited by 108
Muscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Scimeca, G., Nardo, F. D., Santoro, V., Spina, E., & Zoccali, R. A. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.12.011 · Cited by 89
The Effects of Clozapine and Risperidone on Spatial Working Memory in Schizophrenia
McGurk, S. R., Carter, C., GOLDMAN, R. S., Green, M. F., Marder, S. R., Xie, H., Schooler, N. R., & Kane, J. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.1013 · Cited by 89
Verbal fluency in Parkinson’s disease patients on/off dopamine medication
Herrera, E., Cuetos, F., & Ribacoba, R. (2012) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2012.09.016 · Cited by 84
Wagner, M., Quednow, B. B., Westheide, J., Schlaepfer, T. E., Maier, W., & Kühn, K.-U. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300626 · Cited by 80
Do Clozapine and Risperidone Affect Social Competence and Problem Solving?
Bellack, A. S., Schooler, N. R., Marder, S. R., Kane, J. M., Brown, C. H., & Yang, Y. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.364 · Cited by 79
Velligan, D. I., Prihoda, T. J., Sui, D., Ritch, J., Maples, N. J., & Miller, A. L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0505 · Cited by 78
Atypical Antipsychotics, Neurocognitive Deficits, and Aggression in Schizophrenic Patients
KRAKOWSKI, M. I., Czobor, P., & Nolan, K. A. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181855cd6 · Cited by 72
Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia
McGurk, S. R., Green, M. F., Wirshing, W. C., Wirshing, D. A., Marder, S. R., Mintz, J., & Kern, R. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00123-3 · Cited by 66
Kawai, N., 山川, 百., Baba, A., Nemoto, K., Tachikawa, H., Hori, T., Asada, T., & Iidaka, T. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.03.013 · Cited by 65
Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?
Desmarais, J. E., Beauclair, L., & Margolese, H. C. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112447988 · Cited by 59
Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia
Mori, K., Nagao, M., Yamashita, H., Morinobu, S., & Yamawaki, S. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.01.019 · Cited by 59
Fagerlund, B., Mackeprang, T., Gade, A., Hemmingsen, R., & Glenthoj, B. Y. (2004) · CNS Spectrums · doi:10.1017/s1092852900009354 · Cited by 55
Voruganti, L. P., AWAD, A., PARKER, G., Forrest, C. B., USMANI, Y., Fernando, M. L. D., & SENTHILAL, S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.08.002 · Cited by 55
Fagerlund, B., Søholm, B., Fink‐Jensen, A., Lublin, H., & Glenthoj, B. Y. (2007) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000240940.67241.f6 · Cited by 53
Riedel, M. J., Spellmann, I., Strassnig, M., Douhet, A., Dehning, S., Opgen-Rhein, M., Valdevit, R., Engel, R. R., Kleindienst, N., Müller, N., et al. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0739-x · Cited by 53
Bender, S., Dittmann-Balçar, A., Schall, U., Wolstein, J. R., Klimke, A., Riedel, M. J., Vorbach, E.-U., Kühn, K.-U., Lambert, M., Dittmann, R., et al. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005924 · Cited by 52
Harvey, P. D., Bowie, C. R., & Loebel, A. D. (2006) · Journal of Neuropsychiatry · doi:10.1176/jnp.18.1.54 · Cited by 50
Activation of 5-HT6 receptors facilitates attentional set shifting
Burnham, K. E., Baxter, M. G., Bainton, J. R., Southam, E., Dawson, L. A., Bannerman, D. M., & Sharp, T. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1701-6 · Cited by 49
Riedel, M. J., Müller, N., Spellmann, I., Engel, R. R., Musil, R., Valdevit, R., Dehning, S., Douhet, A., Cerovecki, A., Strassnig, M., et al. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0748-9 · Cited by 49
Gallhofer, B., Jaanson, P., Mittoux, A., Tanghøj, P., Lis, S., & Krieger, S. (2007) · Pharmacopsychiatry · doi:10.1055/s-2007-990291 · Cited by 49
Käkelä, J., Panula‐Perälä, J., Oinas, E., Hirvonen, N., Jääskeläinen, E., & Miettunen, J. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12317 · Cited by 46
Mørk, A., Witten, L. M., & Arnt, J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1578-4 · Cited by 40
Kontis, D., Theochari, E., Kleisas, S., Kalogerakou, S., Andreopoulou, A., Psaras, R., Makris, Y., Karouzos, C., & Tsaltas, E. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.029 · Cited by 32
Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients
Lee, S.-M., Chou, Y.-H., Li, M., Wan, F.-J., & Yen, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.03.016 · Cited by 31
Harvey, P. D., Sacchetti, E., Galluzzo, A., Romeo, F., Gorini, B., Bilder, R. M., & Loebel, A. D. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.014 · Cited by 30
Rémillard, S., Pourcher, E., & Cohen, H. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.026 · Cited by 30
Quee, P. J., van der Meer, L., Krabbendam, L., de Haan, L., Cahn, W., Wiersma, D., van Beveren, N., Pijnenborg, G. H. M., Mulder, C. L., Bruggeman, R., et al. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12138 · Cited by 29
Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia
Mortimer, A. M., Joyce, E. M., Balasubramaniam, K., Choudhary, P. C., & Saleem, P. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.865 · Cited by 26
Rémillard, S., Pourcher, E., & Cohen, H. (2007) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617708080090 · Cited by 23
van Veelen, N. M. J., Grootens, K. P., Peuskens, J., Sabbe, B., Salden, M. E., Verkes, R. J., Kahn, R. S., & Sitskoorn, M. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.011 · Cited by 22
Cognition in schizophrenia – a systematic review
Nielsen, R. E. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.09.004 · Cited by 19
Self-citationGurpegui, M., Álvarez, E., Bousoño, M., Ciudad, A., Gómez, J. C., & Olivares, J. M. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.04.003 · Cited by 18
Role of the cholinesterase inhibitors in the treatment of schizophrenia
Pae, C. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.762355 · Cited by 14
Jerrell, J. M., & RAMIREZ, P. M. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.967 · Cited by 11
Grootens, K. P., van Veelen, N. M. J., Sitskoorn, M. M., Sabbe, B., Peuskens, J., Buitelaar, J. K., Verkes, R. J., & Kahn, R. S. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.08.003 · Cited by 11
Nielsen, R. E., Odur, F., Østergaard, T., Munk‐Jørgensen, P., & Nielsen, J. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313499065 · Cited by 9
Self-citationBoulay, L. J., Labelle, A., Bourget, D., Robertson, S., Habib, R., Tessier, P., Tombaugh, T. N., & Milin, R. (2007) · Cognitive Neuropsychiatry · doi:10.1080/13546800601069534 · Cited by 8
Nielsen, R. E., & Nielsen, J. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2175 · Cited by 7
Self-citationAbdolahian, E., Moharreri, F., & Bordbar, M. R. F. (2008) · Cited by 6
Long-term skill proceduralization in schizophrenia
Rémillard, S., Pourcher, E., & Cohen, H. (2009) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617709991123 · Cited by 3
Cited by
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective
Sheffield, J. M., Karcher, N. R., & Barch, D. M. (2018) · Neuropsychology Review · doi:10.1007/s11065-018-9388-2 · Cited by 457
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Vancampfort, D., Rosenbaum, S., Schuch, F. B., Ward, P. B., Probst, M., & Stubbs, B. (2016) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.11.008 · Cited by 225
Metadata
- Authors
- Nielsen, R. E., Levander, S., Kjaersdam Telléus, G., Jensen, S. O. W., Østergaard Christensen, T., & Leucht, S.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2015-01-16
- Volume
- 131
- Issue
- 3
- Pages
- 185-196
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W1970688947
- Cited by
- 270
- References
- 86
- FWCI
- 20.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.